Company intelligence / Profile preview
ExeGi Pharma
Rockville, Maryland, United Statesexegipharma.com ↗
- Ownership
- Private
- Employees
- ~23
- Development stage
- Other
01
Overview
ExeGi Pharma has commercial products including Visbiome probiotic products for various digestive conditions. Their lead investigational drug candidate EXE-346 received FDA IND clearance in January 2023 for clinical trials in patients with excessive stool frequency following ileal pouch-anal anastomosis (J-Pouch).
- Therapeutic areas
- GastroenterologyMetabolic DisordersInfectious Diseases
- Modalities
- Live biotherapeutic productsProbiotics
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Carbonfund.org
Beyond the preview
Go deeper on ExeGi Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ExeGi Pharma.